**REGULATORY FORMS**

**FORMS RELATING TO LISTING**

**Form G**

**GEM**

**Company Information Sheet**

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

|  |  |
| --- | --- |
| **Company name:** | **China Health Group Inc.** |
|  |  |
| **Stock code (ordinary shares):** | **08225** |

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on GEM of The Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the Exchange’s website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 12 March,2024

***A. General***

|  |  |
| --- | --- |
| Place of incorporation: | Cayman Islands |
|  |  |
| Date of initial listing on GEM: | 10 July,2003 |
|  |  |
| Name of Sponsor(s): | N/A |
|  |  |
| Names of directors:*(please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)* | executive Directors：Mr.GUO Xia and Dr. Maria SONG Xuemei ；non-executive Director：Dr. ZHANG Li and Dr. WANG Dajun Denis; independent non-executive Directors：Mr. WU Shuangsi , Dr. NI Binhui , Dr. GUO Tong and Ms. LIU Na |
|   |  |
| Name(s) of substantial shareholder(s):(as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company |

|  |  |
| --- | --- |
| Name of SubstantialShareholder | Approximate percentage ofinterest in the ordinaryshares |
| Winsland Agents Limited(Note 1) | 35.10% |
| Bright Excel Assets Limited(Note 2) | 9.23% |
| Venturepharm Holdings Inc.(Note 3) | 15.01% |
| GUO Xia (Note 4) | 72.69% |

Note 1：Winsland Agents Limited is 100% owned by Mr.GUO Xia.Note 2：Venturepharn Holdings Inc. is 47.63% owned by Mr.GUO Xia and 49% owned by Winsland AgentsLimited.Note 3：Bright Excel Assets Limited is 100% owned by Venturepharn Holdings Inc.Note 4：Winsland Agent Limited, Venturepharm Holdings Inc. and Bright Excel Assets Limited are all controlled corporations of Mr.GUO Xia. In addition to these corporate interests, Mr.GUO Xia personally and directly holds 13.35% shares of the Company. |
|  |  |
| Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company: | N/A |
|  |  |
| Financial year end date: | As of December 31 |
|  |  |
| Registered address: | Scotia Centre, Floor 4, Willow House, Cricket Square, P.O. Box 2804,Grand Cayman, KY1-1112, Cayman Island |
|  |  |
| Head office and principal place of business: | **Head Office in China**Building 17，Jianwai SOHO,Chaoyang District,Beijing,China**Principal Place of Business in Hong Kong**Unit B,19/F, Times Media Centre, 133 Wanchai Road, Wanchai, Hong Kong |
|  |  |
| Web-site address (if applicable): | http://www.chgi.net |
|  |  |
| Share registrar: | **Principal Share Registrar and Transfer Agent**Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor, Royal Bank House 24 Shedden Road, George Town Grand Cayman KY1-1110 Cayman Islands**Hong Kong Branch Share Registrar and Transfer Office**Tricor Standard Limited 17/F, Far East Financial Centre,16 Harcourt Road,Hong Kong |
|  |  |
| Auditors: | KTC PARTNERS CPA LIMITED |

***B. Business activities***

*(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)*

The Group is principally engaged in the provision of fully integrated pharmaceutical services including clinicalresearch services, pharmaceutical research and development and technology transfer.

***C. Ordinary shares***

|  |  |
| --- | --- |
| Number of ordinary shares in issue: | 995351660 |
|  |  |
| Par value of ordinary shares in issue: | HK$0.1 |
|  |  |
| Board lot size (in number of shares): | 20000 |
|  |  |
| Name of other stock exchange(s) on which ordinary shares are also listed: | N/A |

***D. Warrants***

|  |  |
| --- | --- |
| Stock code: | N/A |
|  |  |
| Board lot size: | N/A |
|  |  |
| Expiry date: | N/A |
|  |  |
| Exercise price: | N/A |
|  |  |
| Conversion ratio:*(Not applicable if the warrant is denominated in dollar value of conversion right)* | N/A |
|  |  |
| No. of warrants outstanding: | N/A |
|  |  |
| No. of shares falling to be issued upon the exercise of outstanding warrants: | N/A |

***E. Other securities***

Details of any other securities in issue.

*(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).*

*(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).*

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

|  |
| --- |
| (1) 72,000 Options (granted on 14 December 2005, exercise price of HK$0.45 per share) under share option scheme of 23 May 2003;(2) 1,018,800 Options (granted on 10 August 2006, exercise price of HK$0.36 per share) under share option scheme of 23 May 2003;(3) 2,058,100 Options (granted on 10 May 2007, exercise price of HK$0.625 per share) under share option scheme of 23 May 2003;(4) 5,392,800 Options (granted on 7 April 2009, exercise price of HK$0.435 per share) under share option scheme of 23 May 2003;(5) 24,290,000 Options (granted on 30 June 2015, exercise price of HK$0.45 per share) under share option scheme of 23 May 2003;(6) Convertible Notes of USD 1,000,000 issued to Winsland Agent Limited on 24 December 2014 which could be converted to 77,500,000 shares maximally (the subscription price is HKD 0.1, with an agreed exchange rate of 1.00 USD = 7.75 HKD);(7)14,650,000 Options (granted on 24 March 2021, exercise price of HK$0.504 per share) under share option scheme of 30 June 2015. |

**Responsibility statement**

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Submitted by: |  | Guo Xia  |  |

 (Name)

|  |  |  |  |
| --- | --- | --- | --- |
| Title: |  | Director |  |

 (Director, secretary or other duly authorised officer)

**NOTE**

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the Exchange’s website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.